Results 151 to 160 of about 25,099 (263)

Co‐pathologies and biological processes beyond amyloid‐beta and tau in people with Alzheimer's disease: Evidence from clinical cohort studies

Journal of Internal Medicine, Volume 299, Issue 6, Page 694-710, June 2026.
Abstract Alzheimer's disease (AD) is neuropathologically defined by amyloid‐beta (Aβ) plaques and tau neurofibrillary tangles. However, co‐pathologies and other pathobiological processes are involved in the pathogenesis of AD, contributing to neurodegeneration and clinical symptoms.
Daniel Ferreira, Tomasz Chmiela, Maria Eriksdotter, Clifford R. Jack Jr., Grégoria Kalpouzos, Anna Marseglia, Patrizia Mecocci, Agneta Nordberg, Dorota Religa, Eric Westman   +9 more
wiley   +1 more source

Design, Synthesis, and Evaluation of Coumarin‐Rasagiline Hybrids as Multifunctional Neuroprotective Agents

ChemMedChem, Volume 21, Issue 10, 27 May 2026.
Novel coumarin‐rasagiline hybrid molecules were designed and synthesized as multifunctional agents targeting key pathological mechanisms of neurodegenerative diseases. These compounds exhibited hMAO‐B inhibitory activity, antioxidant and neuroprotective effects, supported by ADMET profiling and molecular modeling studies. The design of hybrid molecules
Aitor Carneiro, Sandra Barreiro, Claudia Sofia Machado, Miguel Pinto, Daniel Chavarria, Manuel Novás, Davide Crucitti, Carlos Fernandes, Maria João Matos   +8 more
wiley   +1 more source

Isolation, Identification and In Silico Evaluation of Novel Cholinesterase Inhibitors from <i>Terminalia triptera</i> Stapf. [PDF]

Molecules
Phan TQ, Huang HT, Wang SL, Nguyen DS, Doan MD, Pham THT, Phan TKT, Truong BP, Nguyen VB.   +8 more
europepmc   +1 more source

Cholinesterase Inhibitors [PDF]

, 2018
Stephanie Behrens, JoAnn Tschanz
openaire   +1 more source

Pharmacoeconomics of Cholinesterase Inhibitors in the Treatment of Alzheimer

Cholinesterase inhibitors constitute one of few treatment options available for Alzheimer Simulation models can be used to bring together existing data and make predictions of the long-term cost effectiveness of treatment.
Linus Jonsson
core  

2-Arylbenzofurans as Selective Cholinesterase Inhibitors: Design, Synthesis, and Evaluation as Alzheimer's Disease Agents. [PDF]

Biomolecules
Delogu GL, Begala M, Novás M, Matos MJ, Piras F, Floris S, Pintus F, Mancinelli M, Era B, Fais A.   +9 more
europepmc   +1 more source

Pneumonia Risk with Cholinesterase Inhibitors [PDF]

Journal of the American Geriatrics Society, 2016
Abid, Iraqi, Terry Lynn, Hughes
openaire   +2 more sources

Syncope and Its consequences in patients with dementia receiving cholinesterase inhibitors: A population-based cohort study

Background Cholinesterase inhibitors are commonly prescribed to treat dementia, but their adverse effect profile has received little attention. These drugs can provoke symptomatic bradycardia and syncope, which may lead to permanent pacemaker insertion ...
Fischer, Hadas D.
core  

Photochemically Assisted Synthesis of Thienobenzotriazole-Based Dual Cholinesterase Inhibitors. [PDF]

Molecules
Jelčić A, Talić S, Odak I, Pongrac P, Štefok D, Škorić I.   +5 more
europepmc   +1 more source

Discovery of <i>Caralluma</i>-derived pregnane glycosides as potent and selective cholinesterase inhibitors: integrated <i>in silico</i> and <i>in vitro</i> evaluation. [PDF]

RSC Adv
Al-Karmalawy AA, Attia MI, Alnajjar R, El-Shiekh RA, Al Khatib AO, Yousef TA, Abdel-Sattar E.   +6 more
europepmc   +1 more source